Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 11
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Influence of TP53 gene mutations and their allelic status in myelodysplastic syndromes with isolated 5q deletion

  • Montoro, Julia
  • Palomo, Laura
  • Haferlach, Claudia
  • Acha, Pamela
  • Chan, Onyee
  • Navarro, Víctor
  • Kubota, Yasuo
  • Schulz, Felicitas Isabel
  • Meggendorfer, Manja
  • Briski, Robert
  • Ali, Najla Al
  • Xicoy, Blanca
  • López-Cadenas, Félix
  • Bosch, Francesc
  • González, Teresa
  • Eder, Lea Naomi
  • Jerez, Andrés
  • Wang, Yu-Hung
  • Campagna, Alessia
  • Santini, Valeria
  • Bernal, Teresa
  • Such, Esperanza
  • Tien, Hwei-Fang
  • Díaz Varela, Nicolás
  • Platzbecker, Uwe
  • Haase, Detlef
  • Díez-Campelo, María
  • Porta, Matteo Della
  • García-Manero, Guillermo
  • Wiseman, Daniel H.
  • Germing, Ulrich
  • Maciejewski, Jaroslaw P.
  • Komrokji, Rami S.
  • Solé, Francesc
  • Haferlach T.
  • Valcárcel, David
Mutations in the TP53 gene, particularly multihit alterations, have been associated with unfavorable clinical features and prognosis in patients diagnosed with myelodysplastic syndrome (MDS). Despite this, the role of TP53 gene aberrations in MDS with isolated deletion of chromosome 5 [MDS-del(5q)] remains unclear. This study aimed to assess the impact of TP53 gene mutations and their allelic state in patients with MDS-del(5q). To that end, a comprehensive analysis of TP53 abnormalities, examining both TP53 mutations and allelic imbalances, in 682 patients diagnosed with MDS-del(5q) was conducted. Twenty-four percent of TP53-mutated patients exhibited multihit alterations, whereas the remaining patients displayed monoallelic mutations. TP53-multihit alterations were predictive of an increased risk of leukemic transformation. The impact of monoallelic alterations was dependent on the variant allele frequency (VAF); patients with TP53-monoallelic mutations and VAF <20% exhibited behavior similar to TP53 wild type, and those with TP53-monoallelic mutations and VAF ≥20% presented outcomes equivalent to TP53-multihit patients. This study underscores the importance of considering TP53 allelic state and VAF in the risk stratification and treatment decision-making process for patients with MDS-del(5q)., V.S. was supported by the Associazione Italiana per la Ricerca sul Cancro (AIRC; grant IG-26537-2021). M.D.P. was supported by the Horizon 2020/2023 program of the European Union (GenoMed4All, 101017549; Synthema project, 1101095530); the TRANSCAN 7 Horizon 2020 program (EuroMDS 20180424); European Union–Next Generation EU, NRRP M6C2 (Investment 2.1 Enhancement and strengthening of biomedical research in the NHS [project PNRR-MAD-2022-12376695]); AIRC Foundation for Cancer Research (29483); and 5 × 1000 MYeloid NEoplasms Research Venture AIRC (project, 21267). F.S. was supported by the Instituto de Salud Carlos III (PI20/0053); TRANSCAN (AECC AC 18/000002); the Generalitat de Catalunya (2017 SGR288 and 2021 SGR00560); and the CERCA Programme/Generalitat de Catalunya, Fundación Internacional Josep Carreras. F.B. was supported by the Instituto de Salud Carlos III (grants PI17/00943 and PI20/01274). D.V. was supported by the Instituto de Salud Carlos III (grants PI17/01088 and PI20/00881)., Peer reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Characterization and Clinical Implications of p53 Dysfunction in Patients With Myelodysplastic Syndromes

  • Zampini, Matteo
  • Riva, Elena
  • Lanino, Luca
  • SAUTA, ELISABETTA
  • Antunes dos Reis, Rita
  • Andrés Ejarque, Rosa María
  • Acha, Pamela
p53 dysfunction; Myelodysplastic syndromes, Disfunción de p53; Síndromes mielodisplásicos, Disfunció de p53; Síndromes mielodisplàsiques, Purpose Tumor Protein 53 (p53) expressed from gene TP53 is a seminal tumor suppressor. We aimed to characterize mutational and nonmutational mechanisms of p53 dysfunction in myelodysplastic syndromes (MDS) and to investigate their clinical effect. Patients and Methods We analyzed a cohort of 6,204 patients with MDS and subsets of patients with available information on RNA sequencing of tumor cells (n = 109), high-dimensional phenotype of immune cells (n = 77), and multiomics analysis (RNA sequencing and proteomics) on single cells (n = 15). An independent validation was performed on 914 patients. Results Biallelic TP53 inactivation was a powerful driver of disease progression and identified high-risk patients, regardless of variant allele frequency. Monoallelic and biallelic inactivation represent disease stages occurring as a multihit process in MDS with TP53 mutations, thus potentially refining the optimal timing of therapeutic interventions in these patients. We identified a subset of MDS (5%) characterized by TP53 wild-type and hyperexpression of abnormal p53 protein in bone marrow progenitors that exhibit dismal outcome. These patients presented upstream p53 signaling aberrations in Pi3K cascade; RAS, WNT, and NF-KB pathways; and MDM2 gene amplification, together with a downstream dysregulation of p53 targets. MDS with p53 dysfunction displayed a distinct immune dysregulation involving myeloid-derived inflammation and impaired antigen presentation, which may be a driver of their poor prognosis and provide the groundwork for innovative immunotherapies. Conclusion The identification of nonmutational p53 dysfunction in MDS may lay the foundation for a mechanistic classification of myeloid neoplasms, moving beyond a purely molecular stratification. The recognition of patients with p53 dysfunction is relevant to provide correct disease-risk assessment and interventions, as well as to refine the design of clinical trials, Supported by European Union—Horizon 2020/2023 program and Innovative Health initiative, IHI (GenoMed4All project #101017549 to M.G.D.P.; U.P.; M.D-C.; P.F.; T.H.; G.C.; Synthema project, #1101095530 to M.G.D.P.; G.C.; Synthia project #101172872 to M.G.D.P.; S. DA.; G.C); European Union—Next Generation EU—NRRP M6C2 (Investment 2.1 Enhancement and strengthening of biomedical research in the NHS—Project PNRR-MAD-2022-12376695 and PNRR-MCNT1-2023-12377648 to M.G.D.P); AIRC Foundation (Associazione Italiana per la Ricerca contro il Cancro, Milan Italy—Project #29483 to M.G.D.P.; #26216 to G.C; #26537 to V.S.; #28131 to G.M.; #31589 to E.R.; #24506 to S.G); 5 × 1000 MYNERVA (Myeloid Neoplasms Research Venture AIRC—project #21267 to M.G.D.P); PRIN (Ministry of University & Research, Italy—Project 20229B28PE to M.G.D.P and G.C); Ricerca Finalizzata (Italian Ministry of Health, Italy—Project NET-2018-12365935 to M.G.D.P.; GR-2021-12374166 to C.D.V. and M.U); TRAIN srl, Milan Italy (to S.DA); ISCIII PI23/01103 Umbrella Summa and PI20/00970 Umbrella (to M.D.C.); Instituto de Salud Carlos III, Ministerio de Economia y Competitividad, Spain (PI 23/00007 to F.S; 2021); SGR 00560 Generalitat de Catalunya (to F.S); CERCA Program/Generalitat de Catalunya, Fundació Internacional Josep Carreras (to F.S). SK, RADR and RMAE are supported by the CRUK City of London Center Award [CTRQQR-2021/100004] at KCL.
Archivo Digital UPM
Publicación Artículo científico (JournalArticle)

The need for multimodal health data modeling: A practical approach for a federated-learning healthcare platform

  • Cremonesi, Francesco
  • Planat, Vincent
  • Kalokyri, Varvara
  • Kondylakis, Haridimos|||0000-0002-9917-4486
  • Sanavia, Tiziana|||0000-0003-3288-0631
  • Mateos, Victor Miguel
  • Singh, Babita
  • Uribe Mayoral, Silvia Alba|||0000-0001-6156-5492
Archivo Digital UPM
Publicación Artículo científico (JournalArticle)

DrOGA: An Artificial Intelligence Solution for Driver-Status Prediction of Genomics Mutations in Precision Cancer Medicine

  • Bastico, Matteo|||0000-0003-4125-6304
  • Fernández García, Anaida|||0000-0002-6102-3121
  • Belmonte Hernández, Alberto|||0000-0002-4009-2662
  • Uribe Mayoral, Silvia Alba|||0000-0001-6156-5492
Archivo Digital UPM
Publicación Artículo científico (JournalArticle)

Propensity Weighted federated learning for treatment effect estimation in distributed imbalanced environments.

  • Almodóvar Espeso, Alejandro|||0009-0006-0900-4026
  • Parras Moral, Juan|||0000-0002-7028-3179
  • Zazo Bello, Santiago|||0000-0001-9073-7927
Archivo Digital UPM
Publicación Tesis doctoral (DoctoralThesis)

Deep Generative Models for Survival Analysis and Synthetic Data Generation in Healthcare

Archivo Digital UPM
Publicación Artículo científico (JournalArticle)

Improving synthetic data generation through federated learning in scarce and heterogeneous data scenarios

  • Alonso de Apellániz, Patricia|||0000-0002-8604-9758
  • Parras Moral, Juan|||0000-0002-7028-3179
  • Zazo Bello, Santiago|||0000-0001-9073-7927
Archivo Digital UPM
Publicación Artículo científico (JournalArticle)

Artificial inductive bias for synthetic tabular data generation in data-scarce scenarios

  • Alonso de Apellániz, Patricia|||0000-0002-8604-9758
  • Jiménez Bejarano, Ana|||0009-0003-8679-4680
  • Arroyo Galende, Borja|||0000-0001-5035-0998
  • Parras Moral, Juan|||0000-0002-7028-3179
  • Zazo Bello, Santiago|||0000-0001-9073-7927
Archivo Digital UPM
Publicación Artículo científico (JournalArticle)

Radiomics feature analysis for survival prediction in multiple myeloma: an automated PET/CT approach

  • Guinea Pérez, Javier|||0009-0006-6656-5612
  • Ceresi, Alessandro|||0009-0002-9857-9518
  • Fernández García, Anaida|||0000-0002-6102-3121
  • Arroyo Galende, Borja|||0000-0001-5035-0998
  • Belmonte Hernández, Alberto|||0000-0002-4009-2662
  • Peluso, Sara|||0000-0003-1924-1093
  • Álvarez García, Federico|||0000-0001-7400-9591
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

A sex-informed approach to improve the personalised decision making process in myelodysplastic syndromes, a multicentre, observational cohort study

  • Maggioni, Giulia|||0000-0002-8652-4854
  • Bersanelli, Matteo
  • Travaglino, Erica
  • Alfonso-Piérola, Ana|||0000-0002-2478-5354
  • Kasprzak, Annika
  • Sangerman Montserrat, Arnan
  • Sauta, Elisabetta|||0000-0002-7830-988X
  • Sala, Claudia|||0000-0002-4889-1047
  • Matteuzzi, Tommaso|||0000-0002-1915-9148
  • Meggendorfer, Manja
  • Gnocchi, Matteo
  • Zhao, Lin-Pierre|||0000-0001-5035-4470
  • Tentori, Cristina Astrid
  • Nachtkamp, Kathrin
  • Dall'Olio, Daniele
  • Mosca, Ettore|||0000-0002-3102-5150
  • Ubezio, Marta|||0000-0003-3862-7119
  • Campagna, Alessia|||0000-0002-8481-759X
  • Russo, Antonio
  • Rivoli, Giulia
  • Bernardi, Massimo|||0000-0002-1334-0851
  • Borin, Lorenza
  • Voso, Maria Teresa|||0000-0002-6164-4761
  • Riva, Marta
  • Oliva, Esther
  • Zampini, Matteo|||0000-0002-9952-1142
  • Riva, Elena|||0000-0002-0701-3889
  • Saba, Elena|||0000-0002-8217-5968
  • D'Amico, Saverio|||0000-0003-1877-8497
  • Lanino, Luca|||0000-0003-2404-8829
  • Tinterri, Benedetta
  • Re, Francesca
  • Bicchieri, Marilena
  • Giordano, Laura|||0000-0002-9587-7870
  • Angelotti, Giovanni|||0000-0003-3264-2721
  • Morandini, Pierandrea|||0000-0002-8615-3766
  • Kubasch, Anne Sophie|||0000-0002-0747-4941
  • Passamonti, Francesco|||0000-0001-8068-5289
  • Rambaldi, Alessandro|||0000-0002-3739-7502
  • Savevski, Victor|||0000-0002-3376-8740
  • Santoro, Armando
  • van de Loosdrecht, Arjan A.
  • Brogi, Alice
  • Santini, Valeria|||0000-0002-5439-2172
  • Kordasti, Shahram|||0000-0002-0347-4207
  • Sanz, Guillermo|||0000-0002-2767-8191
  • Sole, F.|||0000-0002-3251-2161
  • Gattermann, Norbert
  • Kern, Wolfgang|||0000-0002-6452-2874
  • Platzbecker, Uwe|||0000-0003-1863-3239
  • Adès, Lionel
  • Fenaux, Pierre
  • Haferlach, T.|||0000-0003-0196-2837
  • Castellani, Gastone|||0000-0003-4892-925X
  • Germing, Ulrich
  • Diez-Campelo, María|||0000-0002-1467-6779
  • Della Porta, Matteo Giovanni|||0000-0002-6915-5970
Background: Sex is a major source of diversity among patients and a sex-informed approach is becoming a new paradigm in precision medicine. We aimed to describe sex diversity in myelodysplastic syndromes in terms of disease genotype, phenotype, and clinical outcome. Moreover, we sought to incorporate sex information into the clinical decision-making process as a fundamental component of patient individuality. Methods: In this multicentre, observational cohort study, we retrospectively analysed 13 284 patients aged 18 years or older with a diagnosis of myelodysplastic syndrome according to 2016 WHO criteria included in the EuroMDS network (n=2025), International Working Group for Prognosis in MDS (IWG-PM; n=2387), the Spanish Group of Myelodysplastic Syndromes registry (GESMD; n=7687), or the Düsseldorf MDS registry (n=1185). Recruitment periods for these cohorts were between 1990 and 2016. The correlation between sex and genomic features was analysed in the EuroMDS cohort and validated in the IWG-PM cohort. The effect of sex on clinical outcome, with overall survival as the main endpoint, was analysed in the EuroMDS population and validated in the other three cohorts. Finally, novel prognostic models incorporating sex and genomic information were built and validated, and compared to the widely used revised International Prognostic Scoring System (IPSS-R). This study is registered with ClinicalTrials.gov, NCT04889729. Findings: The study included 7792 (58·7%) men and 5492 (41·3%) women. 10 906 (82·1%) patients were White, and race was not reported for 2378 (17·9%) patients. Sex biases were observed at the single-gene level with mutations in seven genes enriched in men (ASXL1, SRSF2, and ZRSR2 p<0·0001 in both cohorts; DDX41 not available in the EuroMDS cohort vs p=0·0062 in the IWG-PM cohort; IDH2 p<0·0001 in EuroMDS vs p=0·042 in IWG-PM; TET2 p=0·031 vs p=0·035; U2AF1 p=0·033 vs p<0·0001) and mutations in two genes were enriched in women (DNMT3A p<0·0001 in EuroMDS vs p=0·011 in IWG-PM; TP53 p=0·030 vs p=0·037). Additionally, sex biases were observed in co-mutational pathways of founding genomic lesions (splicing-related genes, predominantly in men, p<0·0001 in both the EuroMDS and IWG-PM cohorts), in DNA methylation (predominantly in men, p=0·046 in EuroMDS vs p<0·0001 in IWG-PM), and TP53 mutational pathways (predominantly in women, p=0·0073 in EuroMDS vs p<0·0001 in IWG-PM). In the retrospective EuroMDS cohort, men had worse median overall survival (81·3 months, 95% CI 70·4-95·0 in men vs 123·5 months, 104·5-127·5 in women; hazard ratio [HR] 1·40, 95% CI 1·26-1·52; p<0·0001). This result was confirmed in the prospective validation cohorts (median overall survival was 54·7 months, 95% CI 52·4-59·1 in men vs 74·4 months, 69·3-81·2 in women; HR 1·30, 95% CI 1·23-1·35; p<0·0001 in the GEMSD MDS registry; 40·0 months, 95% CI 33·4-43·7 in men vs 54·2 months, 38·6-63·8 in women; HR 1·23, 95% CI 1·08-1·36; p<0·0001 in the Dusseldorf MDS registry). We developed new personalised prognostic tools that included sex information (the sex-informed prognostic scoring system and the sex-informed genomic scoring system). Sex maintained independent prognostic power in all prognostic systems; the highest performance was observed in the model that included both sex and genomic information. A five-to-five mapping between the IPSS-R and new score categories resulted in the re-stratification of 871 (43·0%) of 2025 patients from the EuroMDS cohort and 1003 (42·0%) of 2387 patients from the IWG-PM cohort by using the sex-informed prognostic scoring system, and of 1134 (56·0%) patients from the EuroMDS cohort and 1265 (53·0%) patients from the IWG-PM cohort by using the sex-informed genomic scoring system. We created a web portal that enables outcome predictions based on a sex-informed personalised approach. Interpretation: Our results suggest that a sex-informed approach can improve the personalised decision making process in patients with myelodysplastic syndromes and should be considered in the design of clinical trials including low-risk patients. Funding: European Union (Horizon 2020 and Transcan programs), Italian Association for Cancer Research, Italian Ministry of Health, and Italian Ministry of University and Research.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

Characterization and Clinical Implications of p53 Dysfunction in Patients With Myelodysplastic Syndromes

  • Zampini, Matteo
  • Riva, Elena
  • Lanino, Luca
  • SAUTA, ELISABETTA
  • Antunes dos Reis, Rita
  • Andrés Ejarque, Rosa María
  • Acha, Pamela
p53 dysfunction; Myelodysplastic syndromes, Disfunción de p53; Síndromes mielodisplásicos, Disfunció de p53; Síndromes mielodisplàsiques, Purpose Tumor Protein 53 (p53) expressed from gene TP53 is a seminal tumor suppressor. We aimed to characterize mutational and nonmutational mechanisms of p53 dysfunction in myelodysplastic syndromes (MDS) and to investigate their clinical effect. Patients and Methods We analyzed a cohort of 6,204 patients with MDS and subsets of patients with available information on RNA sequencing of tumor cells (n = 109), high-dimensional phenotype of immune cells (n = 77), and multiomics analysis (RNA sequencing and proteomics) on single cells (n = 15). An independent validation was performed on 914 patients. Results Biallelic TP53 inactivation was a powerful driver of disease progression and identified high-risk patients, regardless of variant allele frequency. Monoallelic and biallelic inactivation represent disease stages occurring as a multihit process in MDS with TP53 mutations, thus potentially refining the optimal timing of therapeutic interventions in these patients. We identified a subset of MDS (5%) characterized by TP53 wild-type and hyperexpression of abnormal p53 protein in bone marrow progenitors that exhibit dismal outcome. These patients presented upstream p53 signaling aberrations in Pi3K cascade; RAS, WNT, and NF-KB pathways; and MDM2 gene amplification, together with a downstream dysregulation of p53 targets. MDS with p53 dysfunction displayed a distinct immune dysregulation involving myeloid-derived inflammation and impaired antigen presentation, which may be a driver of their poor prognosis and provide the groundwork for innovative immunotherapies. Conclusion The identification of nonmutational p53 dysfunction in MDS may lay the foundation for a mechanistic classification of myeloid neoplasms, moving beyond a purely molecular stratification. The recognition of patients with p53 dysfunction is relevant to provide correct disease-risk assessment and interventions, as well as to refine the design of clinical trials, Supported by European Union—Horizon 2020/2023 program and Innovative Health initiative, IHI (GenoMed4All project #101017549 to M.G.D.P.; U.P.; M.D-C.; P.F.; T.H.; G.C.; Synthema project, #1101095530 to M.G.D.P.; G.C.; Synthia project #101172872 to M.G.D.P.; S. DA.; G.C); European Union—Next Generation EU—NRRP M6C2 (Investment 2.1 Enhancement and strengthening of biomedical research in the NHS—Project PNRR-MAD-2022-12376695 and PNRR-MCNT1-2023-12377648 to M.G.D.P); AIRC Foundation (Associazione Italiana per la Ricerca contro il Cancro, Milan Italy—Project #29483 to M.G.D.P.; #26216 to G.C; #26537 to V.S.; #28131 to G.M.; #31589 to E.R.; #24506 to S.G); 5 × 1000 MYNERVA (Myeloid Neoplasms Research Venture AIRC—project #21267 to M.G.D.P); PRIN (Ministry of University & Research, Italy—Project 20229B28PE to M.G.D.P and G.C); Ricerca Finalizzata (Italian Ministry of Health, Italy—Project NET-2018-12365935 to M.G.D.P.; GR-2021-12374166 to C.D.V. and M.U); TRAIN srl, Milan Italy (to S.DA); ISCIII PI23/01103 Umbrella Summa and PI20/00970 Umbrella (to M.D.C.); Instituto de Salud Carlos III, Ministerio de Economia y Competitividad, Spain (PI 23/00007 to F.S; 2021); SGR 00560 Generalitat de Catalunya (to F.S); CERCA Program/Generalitat de Catalunya, Fundació Internacional Josep Carreras (to F.S). SK, RADR and RMAE are supported by the CRUK City of London Center Award [CTRQQR-2021/100004] at KCL.